IVERMECTIN | A210019 | TEVA PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Galderma Laboratories LP et al. v. Teva Pharmaceuticals USA, Inc. 5 patentsANDA 210019ivermectin | D. Del. | 2017-12-11 | Terminated 2020-03-12 | — |
Galderma Laboratories LP et al v. Actavis Laboratories UT Inc et al 6 patentsANDA 210019ivermectin | TXND | 2017-04-21 | Terminated 2017-12-11 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Argenta FDA-2026-P-6705 Argenta submitted a Suitability Petition pursuant to section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA declare a generic ivermectin 1.87% oral liquid suitable for submission in an Abbreviated New Animal Drug Application (ANADA) for horses, with the reference liste | Suitability | 2026-06-11 | Open | Argenta |
Withdrawal of Suitability Petition from Hyman, Phelps & McNamara, P.C. FDA-2026-P-3664 Hyman, Phelps & McNamara, P.C. filed a suitability petition on April 2, 2026 requesting permission under 21 C.F.R. § 314.93(b) to submit an Abbreviated New Drug Application for Ivermectin Tablets in 9 mg, 12 mg, and 15 mg strengths, which the firm withdrew on April 27, 2026. | Suitability | 2026-05-04 | Withdrawn | Hyman |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.